Mycoplasma pneumoniae and its role in asthma
- 1Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
- 2Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
- 3Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
- 4Department of Ocular Pharmacology, Dr R P Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
- 5Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
- Correspondence to: Dr R Guleria Department of Medicine, All India Institute of Medical Sciences, New Delhi 110029, India;randeepg{at}hotmail.com
- Accepted 13 July 2006
- Revised 9 July 2006
Abstract
Mycoplasma pneumoniae (M pneumoniae), primarily recognised as a causative agent of community-acquired pneumonia has recently been linked to asthma. An infection with M pneumoniae may precede the onset of asthma or exacerbate asthma symptoms. Chronic infection with M pneumoniae has been suspected to play a part in some patients with asthma. The role of immunoglobulin E-related hypersensitivity and induction of T helper type 2 immune response leading to inflammatory response in M pneumoniae-infected patients with asthma have also been proposed. Use of macrolides in reducing asthma symptoms only in M pneumoniae-infected patients supports the use of macrolides in patients with asthma having M pneumoniae infection. As macrolides are both antimicrobial and anti-inflammatory drugs, the therapeutic role of their biphasic nature in reducing asthma symptoms needs further attention in clinical research.
- Mycoplasma pneumoniae
- bronchial asthma
- hyper-responsiveness
- asthma exacerbation
- cytokines
- macrolides
- clarithromycin
Footnotes
-
Competing interests: None declared.







